argenx reports positive Phase 3 ALKIVIA topline results
argenx (ARGX) announces positive topline results from its Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.